These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 11398592

  • 1. [Selected parameters of bone metabolism in hemodialyzed and peritoneally dialyzed patients].
    Małyszko J, Zbroch E, Wołczyński S, Myśliwiec M.
    Przegl Lek; 2000; 57(12):711-3. PubMed ID: 11398592
    [Abstract] [Full Text] [Related]

  • 2. Clearance of osteocalcin in adults with end-stage renal disease undergoing CAPD.
    Klein JR, Grunewald RW, Steffgen J, Franz HE.
    Adv Perit Dial; 1991; 7():225-9. PubMed ID: 1680431
    [Abstract] [Full Text] [Related]

  • 3. [Concentration of leptin in patients on hemodialysis and peritoneal dialysis].
    Zbroch E, Małyszko J, Wołczyński S, Hryszko T, Myśliwiec M.
    Pol Arch Med Wewn; 1999 Jun; 101(6):503-8. PubMed ID: 10754736
    [Abstract] [Full Text] [Related]

  • 4. Plasma insulin-like growth factor-1 and bone formation parameters in predialysis chronic renal failure.
    Coen G, Mazzaferro S, Ballanti P, Bonucci E, Bondatti F, Pasquali M, Perruzza I, Manni M, Sardella D.
    Miner Electrolyte Metab; 1991 Jun; 17(3):153-9. PubMed ID: 1779936
    [Abstract] [Full Text] [Related]

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 6. Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease.
    Grzegorzewska AE, Młot M.
    Rocz Akad Med Bialymst; 2004 Nov; 49():190-2. PubMed ID: 15631341
    [Abstract] [Full Text] [Related]

  • 7. Serum leptin, resistin, and lipid levels in patients with end stage renal failure with regard to dialysis modality.
    Taskapan MC, Taskapan H, Sahin I, Keskin L, Atmaca H, Ozyalin F.
    Ren Fail; 2007 Nov; 29(2):147-54. PubMed ID: 17365928
    [Abstract] [Full Text] [Related]

  • 8. The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels.
    Borazan A, Ustün H, Ustundag Y, Aydemir S, Bayraktaroglu T, Sert M, Yilmaz A.
    Mediators Inflamm; 2004 Jun; 13(3):201-4. PubMed ID: 15223612
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Insulin-like growth factor system components in relation to erythropoietin therapy and bone metabolism in dialyzed patients and kidney transplant recipients.
    Małyszko J, Wołczyński S, Zbroch E, Brzósko S, Małyszko J, Myśliwiec M.
    Nephron; 2002 Mar; 90(3):282-9. PubMed ID: 11867949
    [Abstract] [Full Text] [Related]

  • 11. Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones.
    Grzegorzewska AE, Młot M.
    Rocz Akad Med Bialymst; 2004 Mar; 49():193-6. PubMed ID: 15631342
    [Abstract] [Full Text] [Related]

  • 12. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH.
    Ueda M, Inaba M, Okuno S, Maeno Y, Ishimura E, Yamakawa T, Nishizawa Y.
    Life Sci; 2005 Jul 22; 77(10):1130-9. PubMed ID: 15978265
    [Abstract] [Full Text] [Related]

  • 13. Markers of bone metabolism in hemodialyses and hemodiafiltration.
    Małyszko J, Małyszko JS, Koźminski P, Pawlak K, Wołczynski S, Myśliwiec M.
    Ren Fail; 2007 Jul 22; 29(5):595-601. PubMed ID: 17654323
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Association between phosphate removal and markers of bone turnover in haemodialysis patients.
    Albalate M, de la Piedra C, Fernández C, Lefort M, Santana H, Hernando P, Hernández J, Caramelo C.
    Nephrol Dial Transplant; 2006 Jun 22; 21(6):1626-32. PubMed ID: 16490746
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Clinical evaluation of osteocalcin in chronic hemodialysis patients].
    Nishio S, Hayashi S, Yoshihara H, Kobayagawa H.
    Hinyokika Kiyo; 1989 Nov 22; 35(11):1839-45. PubMed ID: 2618881
    [Abstract] [Full Text] [Related]

  • 18. [Acute effects of hemodialysis on circulating parathormone, osteocalcin and alkaline phosphatase in patients with chronic renal failure].
    Broulík P, Hrubý M.
    Cas Lek Cesk; 1993 Nov 22; 132(22):681-3. PubMed ID: 8293434
    [Abstract] [Full Text] [Related]

  • 19. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
    Lobo J, Santos F, Grosso D, Lima R, Barreira AL, Leite M, Mafra D, Abdalla DS.
    Nephron Clin Pract; 2008 Nov 22; 108(4):c298-304. PubMed ID: 18434752
    [Abstract] [Full Text] [Related]

  • 20. Serum level of intact parathyroid hormone and other markers of bone metabolism in dialyzed patients.
    Grzegorzewska AE, Młot-Michalska M.
    Adv Perit Dial; 2007 Nov 22; 23():162-5. PubMed ID: 17886625
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.